Results of the phase III roll over study in adults with GHD “12-Month effects of once-weekly sustained-release growth hormone treatment in adults with GH deficiency” are published online in the Pituitary Journal.

Results of the phase III roll over study in adults with GHD “12-Month effects of once-weekly sustained-release growth hormone treatment in adults with GH deficiency” are published online in the Pituitary Journal. The results of the study show that LB03002 GH replacement in adult patients with GHD can be successfully carried out using a sustained-release formulation given once-weekly over a prolonged period of 52 weeks, in addition demonstrating a reassuring safety profile.

Please click here to read the study